Cargando…
Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis
BACKGROUND: To analyze whether medical care is in accordance with guidelines for secondary prevention of myocardial infarction (MI), or stroke in patients with type 2 diabetes from Germany and Austria. METHODS: 29,325 patients (≥20 years of age) with type 2 diabetes and MI, or stroke, documented bet...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855873/ https://www.ncbi.nlm.nih.gov/pubmed/27141979 http://dx.doi.org/10.1186/s12933-016-0391-8 |
_version_ | 1782430429498834944 |
---|---|
author | Bohn, Barbara Schöfl, Christof Zimmer, Vincent Hummel, Michael Heise, Nikolai Siegel, Erhard Karges, Wolfram Riedl, Michaela Holl, Reinhard W. |
author_facet | Bohn, Barbara Schöfl, Christof Zimmer, Vincent Hummel, Michael Heise, Nikolai Siegel, Erhard Karges, Wolfram Riedl, Michaela Holl, Reinhard W. |
author_sort | Bohn, Barbara |
collection | PubMed |
description | BACKGROUND: To analyze whether medical care is in accordance with guidelines for secondary prevention of myocardial infarction (MI), or stroke in patients with type 2 diabetes from Germany and Austria. METHODS: 29,325 patients (≥20 years of age) with type 2 diabetes and MI, or stroke, documented between 2006 and 2015 were selected from the Diabetes-Patienten-Verlaufsdokumentation database. We analyzed medication, clinical characteristics, and lifestyle factors according to national secondary prevention guidelines in patients with MI, or stroke, separately. RESULTS: HbA(1C) <7.5 % was achieved in 64.9 % (MI), and in 61.1 % (stroke) of patients. LDL <100 mg/dl was documented in 56.2 % (MI), and in 42.2 % (stroke). Non-smoking was reported in 92.0 % (MI), and in 93.1 % (stroke), physical activity in 9.6 % (MI), and 5.5 % (stroke). Target values of blood pressure (<130/80 mmHg in MI, 120/70–140/90 in stroke) were reached in 67.0 % (MI), and in 89.9 % (stroke). Prescription prevalence of inhibitors of platelet aggregation (IPA) was 50.7 % (MI), and 31.7 % (stroke). 57.0 % (MI), and 40.1 % (stroke) used statins, 65.1 % (MI), and 65.8 % (stroke) used any type of antihypertensives, and ACE inhibitors were prescribed in 49.7 % (MI), and 41.3 % (stroke). A body mass index (BMI) <27 kg/m(2) and the use of beta blockers were only recommended in subjects with MI. Of the patients with MI, 32.0 % had a BMI <27 kg/m(2), and 59.5 % used beta blockers. CONCLUSIONS: Achievement of treatment goals in secondary prevention of MI, or stroke in subjects with type 2 diabetes needs improvement. Target goals were met more frequently in patients with MI compared to subjects with stroke. Especially the use of IPA was very low in patients with stroke. There remains great potential to reduce the risk of repeated macrovascular events and premature death, as well as to increase patients’ quality of life. |
format | Online Article Text |
id | pubmed-4855873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48558732016-05-05 Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis Bohn, Barbara Schöfl, Christof Zimmer, Vincent Hummel, Michael Heise, Nikolai Siegel, Erhard Karges, Wolfram Riedl, Michaela Holl, Reinhard W. Cardiovasc Diabetol Original Investigation BACKGROUND: To analyze whether medical care is in accordance with guidelines for secondary prevention of myocardial infarction (MI), or stroke in patients with type 2 diabetes from Germany and Austria. METHODS: 29,325 patients (≥20 years of age) with type 2 diabetes and MI, or stroke, documented between 2006 and 2015 were selected from the Diabetes-Patienten-Verlaufsdokumentation database. We analyzed medication, clinical characteristics, and lifestyle factors according to national secondary prevention guidelines in patients with MI, or stroke, separately. RESULTS: HbA(1C) <7.5 % was achieved in 64.9 % (MI), and in 61.1 % (stroke) of patients. LDL <100 mg/dl was documented in 56.2 % (MI), and in 42.2 % (stroke). Non-smoking was reported in 92.0 % (MI), and in 93.1 % (stroke), physical activity in 9.6 % (MI), and 5.5 % (stroke). Target values of blood pressure (<130/80 mmHg in MI, 120/70–140/90 in stroke) were reached in 67.0 % (MI), and in 89.9 % (stroke). Prescription prevalence of inhibitors of platelet aggregation (IPA) was 50.7 % (MI), and 31.7 % (stroke). 57.0 % (MI), and 40.1 % (stroke) used statins, 65.1 % (MI), and 65.8 % (stroke) used any type of antihypertensives, and ACE inhibitors were prescribed in 49.7 % (MI), and 41.3 % (stroke). A body mass index (BMI) <27 kg/m(2) and the use of beta blockers were only recommended in subjects with MI. Of the patients with MI, 32.0 % had a BMI <27 kg/m(2), and 59.5 % used beta blockers. CONCLUSIONS: Achievement of treatment goals in secondary prevention of MI, or stroke in subjects with type 2 diabetes needs improvement. Target goals were met more frequently in patients with MI compared to subjects with stroke. Especially the use of IPA was very low in patients with stroke. There remains great potential to reduce the risk of repeated macrovascular events and premature death, as well as to increase patients’ quality of life. BioMed Central 2016-05-03 /pmc/articles/PMC4855873/ /pubmed/27141979 http://dx.doi.org/10.1186/s12933-016-0391-8 Text en © Bohn et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Bohn, Barbara Schöfl, Christof Zimmer, Vincent Hummel, Michael Heise, Nikolai Siegel, Erhard Karges, Wolfram Riedl, Michaela Holl, Reinhard W. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis |
title | Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis |
title_full | Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis |
title_fullStr | Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis |
title_full_unstemmed | Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis |
title_short | Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis |
title_sort | achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a german/austrian dpv-multicenter analysis |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855873/ https://www.ncbi.nlm.nih.gov/pubmed/27141979 http://dx.doi.org/10.1186/s12933-016-0391-8 |
work_keys_str_mv | AT bohnbarbara achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT schoflchristof achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT zimmervincent achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT hummelmichael achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT heisenikolai achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT siegelerhard achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT kargeswolfram achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT riedlmichaela achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT hollreinhardw achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis AT achievementoftreatmentgoalsforsecondarypreventionofmyocardialinfarctionorstrokein29325patientswithtype2diabetesagermanaustriandpvmulticenteranalysis |